Pancreatic ductal adenocarcinoma (PDAC) is a digestive malignancy with a high rate of KRAS oncogenic mutation,[1] resulting in a 5‐year survival rate of less than 12%.[2] Additionally, 90% of PDAC patients with KRAS mutations exhibit extensive perineural invasion (PNI) at an early stage, resulting in a nearly 23‐month reduction in their overall survival (OS).[3] Thus, PDAC patients with KRAS mutations and PNI exhibit a highly aggressive phenotype. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.